Baxter International Inc. has initiated a voluntary recall to the hospital/user level of one lot of 5% Dextrose Injection, USP and four lots of 0.9% Sodium Chloride Injection, USP due to particulate matter found in the solutions.

Baxter recall

Injecting a product containing particulate matter may result in blockages of blood vessels, which can result in stroke, heart attack or damage to other organs such as the kidney or liver. There is also the possibility of allergic reactions, local irritation and inflammation in tissues and organs.

(Hospira recalls one lot of Lidocaine)

Sodium Chloride Injection, USP is an intravenously administered injectable indicated as a source of water and electrolytes and for use as a priming solution in hemodialysis procedures. Dextrose Injection, USP is an intravenously administered injectable indicated as a source of water and calories. These 50 mL and 100 mL containers are primarily used for admixture of medication and as priming solutions. Products affected by this recall were packaged in flexible plastic containers, with 96 containers per carton, Baxter said.

Affected product was distributed to health care centers and distributors in Saudi Arabia, Singapore, United Arab Emirates, and the United States and Puerto Rico. The affected lots were distributed to customers between May 2012 and October 2013.

Baxter has notified customers, who are being directed not to use product from the recalled lots. Customers that have product affected by this recall should stop use and arrange for return. Unaffected lot numbers can continue to be used according to the instructions for use.